

Acute coronary syndrome

PRAJONGJIT CHAMSA-ARD MD.

11 March 2011


About the acute coronary syndrome

- Definition
- Pathophysiology
- Diagnosis
- Differential diagnosis
- Treatment


What is the acute coronary syndrome?

- Acute
- Left-threatening
- Coronary event


The clinical presentation of the ischaemic heart disease




Coronary arteries



© 1997 HeartPoint



Coronary arteries (posterior view)



- 1. LAD (ด้านหน้า)
- 2. LCX (ด้านข้าง)
- 3. RCA(ด้านขวา)

World Health Organization

Diagnosis of Myocardial Infarction
requires ≥ 2 of the following


- 1. Prolonged ischemic-type chest discomfort
- 2. Serial ECG changes
- 3. Rise and fall of serum cardiac markers

Pathophysiology:


Acute coronary perfusion deficit

- Mechanism:
 - coronary plaque rupture (95%) → lead to partial or total coronary occlusion
 - coronary spasm
 - Prinzmetal angina (transient ST elevation)
 - myocardial infarction (if the ischemic period is too long)
 - coronary embolisation

Degenerative change




ผนังหลอดเลือดหัวใจปกติ





macrophages

free cholesterol


foam cells



ผนังหลอดเลือดหัวใจเสื่อม




หลอดเลือดหัวใจเริ่มตีบ




internal
elastic lamina



fibrous s
(necrotic)




หลอดเลือดหัวใจตีบ



หลอดเลือดหัวใจอุดตัน



T cell
 Platelet
 Fibrous cap
 Lipid-rich pool
 Foam cell
 Smooth-muscle cell




Vulnerable plaque

Large, eccentric lipid-rich pool
 Foam-cell infiltration of lipid core secreting tissue factor
 Thin fibrous cap
 Local inflammatory environment, including neutrophils, T cells, macrophages, smooth-muscle cells, and cytokines promoting cap breakdown by secretion of matrix metalloproteinases

Plaque rupture

Triggers: physical exertion, mechanical stress due to an increase in cardiac contractility, pulse rate, blood pressure, and possibly, vasoconstriction

T cell
 Platelet
 Fibrin
 Foam cell
 Smooth-muscle cell



Thrombus formation

Systemic thrombogenicity
 Platelet activation, adhesion, and aggregation
 Coagulation-pathway activation and thrombin formation
 Fibrinogen conversion to fibrin with cross-linking of bands

Complete coronary occlusion


Spontaneous lysis, repair, and wall remodeling

Incomplete coronary occlusion

Acute myocardial infarction

Temporary resolution of instability
 Future high-risk coronary lesion

Unstable angina or non-Q-wave myocardial infarction



partial
coronary occlusion

total
coronary occlusion

By ECG
(at admission)

biomarker

ECG
(at discharge)

Pathophysiology:

Acute coronary perfusion deficit


- Mechanism:
 - coronary plaque rupture (95%) → lead to partial or total coronary occlusion
 - coronary spasm
 - Prinzmetal angina (transient ST elevation)
 - myocardial infarction (if the ischemic period is too long)
 - coronary embolisation

Prinzmetal angina

- Temporary partial or total coronary occlusion due to coronary spasm
- mainly at the middle adge women
- it can lead to malignant arrythmia (VF)
- Need an urgent coronary angiography
- prognosis is different:
 - with coronary stenosis w/o revascularisation poor, with revascularisation is good
 - w/o coronary stenosis with medical treatment is good


Prinzmetal angina

Transient ST elevation during pain on the 24 hour Tape Recorder




Transient coronary occlusion w/o stenosis due to coronary spasm

A



Normal coronary flow after intracoronary nitroglycerin administration

B



C

Pathophysiology:

Acute coronary perfusion deficit

- Mechanism:
 - coronary plaque rupture (95%) → lead to partial or total coronary occlusion
 - coronary spasm
 - Prinzmetal angina (transient ST elevation)
 - myocardial infarction (if the ischemic period is too long)
 - coronary embolisation (rare)

Pathophysiology:

Acute coronary perfusion deficit

- Mechanism:

other causes

- with stable coronary stenosis without plaque rupture
 - extreme exercise
 - sudden dropped oxygen transport capacity (major bleeding)

Ischemic-Type Chest Pain

- Typically prolonged (>30 min) and at rest
- Pattern and accompanying symptoms (including “a sense of doom”)
- Can be mimicked by pericarditis, reflux, spontaneous pneumothorax, musculoskeletal disease (costochondritis)
- Clinical Pearl = 3 serious causes of severe chest pain: acute MI, aortic dissection, pulmonary embolus

Diagnosis

- Family history –close relative with acute MI in young age or sudden death
- Medical history for the risk factor
 - : smoking state
 - : hypertension
 - : hypercholesterolemia
 - : diabetes

Diagnosis


- Current complaint
 - : pain
 - : shortness of breath
 - : sweating
 - : dizziness
 - : fear of death



Diagnosis

- current complaint:
 - pain
 - there are a lot of important data of the pain:
 - **localization**
 - **radiation**
 - onset of the pain
 - the type (press, smart, cutting)
 - dynamic of the pain (continuously, ongoing, undulating)
 - answer to the medical therapy
 - sometimes the MI patient doesn't have a pain – mostly from the diabetic patients through the autonomic neuropathy

Diagnosis

- current complaint:
 - pain





อาการแน่นกลางหน้าอก หรือลิ้นปี่ ที่เป็นบริเวณกว้าง

๑ ใน ๓ จะมีเจ็บร้าวไปที่ คอ ขากรรไกรล่าง หรือ ด้านในของแขน

Diagnosis – physical examination

- presence of pallor – extracardiac cause – anemia!
- cyanosis
- shortness of breath, orthopnoe, periodic (Cheyne-Stokes) respiration
- distention of the neck veins

Diagnosis – physical examination

- Pulmonary congestion
- Blood pressure – cardiogenic shock?
- Murmur – complication?

Electrocardiography (ECG)

- ACC/AHA guidelines require ECG performed within 5 minutes of presentation to the ER with symptoms of chest pain


ECG with ST-segment elevation (STEMI)

- ST segment elevation (with compatible history)
specificity=91%, sensitivity =46%
- The higher the elevation and the more the leads involved
the larger the infarction and the greater the mortality
- Watch out for other causes of ST- segment elevation , such
as pericarditis, old MI (aneurysm) and normal variant
(early repolarization)

ECG without ST-segment elevation(NSTEMI)

- Half of acute MI patients present without ST-segment elevation
- May see ST-segment depression , T wave inversion , non specific ST-T wave changes or rarely entirely normal ECG
- Left bundle branch block

Diagnosis – ECG - STEMI




Hyperacute phase of extensive antero-lateral myocardial infarction.

Diagnosis – ECG - STEMI



Diagnosis – ECG - STEMI



Acute inferior
myocardial infarction.

In case of STEMI...

Very important the *quick* diagnosis!!!

TIME = MYOCARDIUM = LIFE!


If the time window ≤ 12 h
open artery theory =
open the occluded coronary artery –
save the myocardium!

If the patient has typical chest pain
+ typical ECG with acut STEMI –
it is enough to diagnosis!




Progression of myocardial injuries


- ▶ Ischemia—Lack of oxygen to the cardiac tissue, represented by ST segment depression, T wave inversion, or both
- ▶ Injury—Arterial occlusion with ischemia, represented by ST segment elevation
- ▶ Infarction—Death of tissue, represented by a pathological Q wave




Anterior MI




Occlusion of proximal left anterior descending coronary artery





Lateral MI




Occlusion of left circumflex coronary artery, marginal branch of left circumflex artery, or diagonal branch of left anterior descending artery



Inferior MI



Posterior MI




Laboratory Findings

myocardium injury

releasing biomarkers


Troponin T,I,C and
MB fraction of creatine
kinase (CK-MB)

If the patient has only the Troponin
elevation: microinfarction



rapidly and higher peak of cardiac marker after successful reperfusion therapy: „WASH-OUT PHENOMENON”

Laboratory Findings



Different type of enzyme kinetics

Differential diagnosis




- From other life-threatening acute chest-disease:
 - pulmonary embolism
 - aortic dissection
- From other disease:
 - pleuritis
 - gastro-oesophageal disease
 - myositis
 - gastric or duodenal ulcer
 - gallbladder pain


Differential diagnosis

- From other life-threatening acute chest-disease:
 - pulmonary embolism
 - pain related to breathing, sharp
 - blood-gas report (hypoxaemia and hypocapnia)
 - ECG sign S_I-Q_{III}
 - echocardiography (transthoracic and transoesophageal)
 - Ultrasound image from the lower limbs (search for deep vein thrombi)
 - CT – direct image of the pulmonary emboli
 - SCAN (ventilation and perfusion scintigraphy together)

Differential diagnosis


- From other life-threatening acute chest-disease:
 - pulmonary embolism
 - aortic dissection
- From other disease:
 - pleuritis
 - gastro-oesophageal reflux
 - myositis
 - gastric or duodenal perforation
 - gall bladder pain





STEMI

- Quick diagnosis (Typical chest pain and ECG)
- Time window?
- Prehospital therapy
 - aspirin
 - morphine
 - nitroglycerin
 - again the pain, hypertensive state, left ventricular failure
 - Attention! Right ventricular infarction can cause sever hypotension!
 - O2
- Send the patient to the hospital



ACS

STEMI

UA/NSTEMI

STEMI ≤ 12 h

STEMI >12 h

risk stratification

Primary PCI ((CABG))

cardiogenic shock ≤ 36 h

high risk
 • early high risk
 • late high risk

Thrombolysis


rescue PCI ((CABG))

PCI ((CABG))

PCI ((CABG))

med. th.
 non-inv.im. (echo, stress-test etc.)

Open artery theory



ACS

STEMI

UA/NSTEMI

STEMI \leq 12 h

STEMI $>$ 12 h

risk stratification

Primary PCI
(CABG)

cardiogenic
shock \leq 36 h

high risk
• early high risk
• late high risk

Thrombolysis

rescue PCI
(CABG)

PCI (CABG)

PCI (CABG)

med. th.
non-inv.im. (echo, stress-test etc.)

Open artery theory

Acute Management of MI

General Measures

- Oxygen: modest hypoxemia (common V/Q mismatch)
- Bed rest
- ECG monitoring: 48-72 hours for acute MI, 12-36 hours to rule out MI
- Analgesics: commonly underdosed (pain, catecholamines, myocardial oxygen demand)

Analgesic - Morphine Sulfate

- Good dose response, easily reversible; 2-5mg every 5-30 minutes
- Peripheral venous and arterial dilation; blocks sympathetic efferent discharge at CNS level; reduces preload and afterload - good with CHF
- Side effects: hypotension and bradycardia occur rarely; respiratory depression with severe COPD

Acute Management of MI: Pharmacotherapy - Aspirin

- Acute Aspirin - ASA 325mg chewed immediately on presentation
- ISIS-2 results (Lancet 2:349, 1988) based on 17,187 patients; reduced one month mortality 19%
- Additive effect to streptokinase - reduced one month mortality 23%
- Give immediately to anyone with suspected MI unless **STRONG** contraindication

Acute Management of MI: Pharmacotherapy - NTG

- Sublingual NTG given to all patients initially if systolic BP >90
- Avoid long acting nitrates initially
- Data from trials show acute MI pain due to ongoing ischemia rather than completed myocardial necrosis so NTG may be rational choice for ongoing ischemic pain
- Helpful in pulmonary edema

Acute Management of MI: NTG (continued)

- Dosage: 5-10 $\mu\text{g}/\text{min}$, increase 5-10 $\mu\text{g}/\text{min}$ every 5 to 10 minutes
- Nitrate tolerance after > 24 hours
- Recommend routinely for most MI's for 24-48 hours (particularly with CHF), hypertension or recurrent ischemia, and regularly for unstable angina

Acute Management of MI: NTG Side Effects

- Headache - quite common, decreases with time
- Hypotension - particular care needed with right ventricular infarction
- Hypoxemia from V/Q mismatch - need to be alert for this phenomenon
- Bradycardia with hypotension - under appreciated

Acute Management of MI: Pharmacotherapy - Heparin

- Potential Uses
 - To aid in recannalization or reduce reocclusion of coronary artery
 - To reduce systemic embolism and stroke from left ventricle mural thrombus
 - To reduce deep venous thrombosis and pulmonary embolus

Acute Management of MI: Heparin (continued)

- Definite indication for IV heparin (for 48 hours)
 - Unstable angina
 - As adjunctive therapy for thrombolysis with tissue plasminogen activator (tPA)
 - As adjunctive therapy for primary angioplasty
 - Large anterior MI or known mural thrombus (to reduce stroke)

Acute Management of MI: Heparin (continued)

- Ideal target dose: aPTT = 50-75 sec; higher doses lead to intracranial hemorrhage
- Be aware of hypercoagulable state with abrupt termination of heparin
- Give to large majority of patients with acute coronary syndromes

Heparin-Induced Thrombocytopenia

- 3% incidence
- Most often occurs after day 4
- Check platelets daily
- Associated with prothrombotic events, particularly deep venous thrombosis

Acute Management of MI: Pharmacotherapy - Lidocaine

- Treatment of choice for sustained ventricular tachycardia (VT) and fibrillation (VF) and shock if necessary
- More benign ventricular arrhythmias (including nonsustained VT) generally not treated
- Prophylactic use no longer advised - meta-analysis of 14 randomized trials showed ↓VF by 33% but slight ↑mortality possibly due to asystole and electromechanical dissociation

Acute Management of MI: Lidocaine (continued)

- Dose: 1mg/kg (100mg max) followed by 0.5mg/kg every 10 minutes to 4mg/kg max
- Maintenance 20-50 μ g/kg/min IV
- $t_{1/2}$ = 1-2 hours in normal individuals, >20 hours with bad CHF secondary to \downarrow liver metabolism

Acute Management of MI: Lidocaine Side Effects

- Frequent
- CNS : dizziness, confusion, drowsiness, nausea, slurred speech, perioral numbness, tremor, respiratory depression, double vision
- Cardiovascular: bradycardia, hypotension, sinus arrest
- Consider IV Amiodarone and procainamide as alternatives

Acute Management of MI: Pharmacotherapy-Beta Blockers

- Beta-blockers significantly ↓ MI size by enzymes, ST segments, etc.
 - MIAMI trial (Eur H J, 6:199,1985) 5600 patients, MI smaller with metoprolol if treated within 7 hours, 15-day mortality reduced
 - TIMI II (NEJM 320:618,1989) B-blocker + thromolytics ↓ ischemia and reinfarction but not mortality

Acute Management of MI: Beta-blockers (continued)

- Mortality evident by day 1 and sustained
- Quickly reversed by isoproterenol
- Surprisingly safe
- Good candidate patients - early presentation, ↑HR, ↑BP, anterior MI
- Contraindications - HR<60, BP<100, moderate/severe CHF, AV block, bad COPD
- Typical dose metoprolol 5mg IV every 5 minutes x 3

Acute Management of MI: Pharmacotherapy - Ace Inhibitor

- Definite indication - within 24 hours of moderate or large anterior MI's or MI's associated with CHF or LVEF <40%
- Controversial indication - all MI's within 24 hours, stopped in 4-6 weeks if no CHF or significant left ventricular dysfunction (LVEF<40%) evident

All Early ACE Inhibitor Trails Have Shown Mortality Benefit

- SAVE Study - 2231 patients 3-13 days post-MI, half received 50mg captopril TID: ↓4 year mortality 19%, ↓severe CHF 35%, ↓recurrent MI 25% (NEJM 327:669,1992)
- GISSI-3 - lisinopril in >19,000 patients ↓mortality at 6 weeks 12% (Lancet 343:1115,1994)

All ACE Inhibitor Trails Show Mortality Benefit (continued)

- ISIS-4 - 58,000 patients showed 7% ↓ 5 week mortality with captopril (Lancet 345:8951,1995)
- Meta-analysis: 4.6 fewer deaths per 1000 patients treated
- Contraindication: SBP<100, significant renal failure
- Give ACE inhibitors in the first few hours to all MI's or at least large MI's or MI's associated with CHF or ↓ejection fraction

Acute Management of MI: Pharmacotherapy-Calcium Channel Antagonists

- Generally best avoided unless patient experiences continued ischemia unresponsive to nitrates or beta-blocker

Acute Management of MI: Pharmacotherapy - Magnesium

- Meta-analysis - showed 50% ↓mortality (BMJ 303:1499,1991)
- LIMIT-2 trial - 24% ↓mortality with 8mmol MgSO₄ for 5 min then 3 mmol/hour (Lancet 339:8809,1992)
- ISIS-4 - no difference in mortality with Mg⁺⁺ but given late (Lancet 345:8951,1995)
- Mg⁺⁺ best used in high risk (elderly) and non-thrombotic candidates

Acute Management of MI: Reperfusion by Thrombolysis

- Rationale:
 - ST-segment elevation MI nearly always due to acute coronary thrombosis
 - All thrombolytic agents work by converting plasminogen to plasmin
- Clearly saves lives:
 - Meta-analysis - 35 day mortality ↓ by 21%
 - 18 lives per 10000 treated

Acute Management of MI: Reperfusion by Thombolysis (continued)

- GISSI - 11,700 patients using streptokinase ↓mortality 18% with difference persisting at one year (Lancet 2:871,1987)
- ISIS-2 - 17,200 patients using streptokinase (+ASA) ↓one year mortality 23% with significant improvement noted even when treatment started 12-24 hours after the onset of symptoms

Acute Management of MI: Reperfusion by Thrombolysis (continued)

- Underused - Use in good candidates 50-70%; in patients >65 years = 20%
- Indication:
 - ST elevation
 - LBBB
 - MI <12 hours since onset

Acute Management of MI: Reperfusion by Thrombolysis (continued)

- Controversial potential contraindications:
 - Patients > 75 years old
 - Late presentations (12-24 hours)
 - Hypertension (>180/100 mmHg)
- Clear contraindications:
 - CVA/TIA within one year
 - Hemorrhagic CVA at any time
 - Intracranial neoplasm
 - Active internal bleeding (not including menses)
 - Suspected aortic dissection

Acute Management of MI: Reperfusion by Thrombolysis (continued)

- Time to delivery is critical:
 - <1 hour - 35 lives saved per 1000; 7-12 hours - 16 lives saved per 1000
 - Community education programs
 - Educate your own patients with coronary artery disease
 - Hospital goal - “door to needle” time of <30 minutes
 - Thrombolytic “code” team

Acute Management of MI: Choice of Thrombolytic Agent

- tPA
 - Less allergic reactions
 - Less fibrinogen depletion (“clot selective”)
 - Faster thrombolysis
 - Slightly lower overall mortality
- Streptokinase (SK)
 - Less expensive
 - Lower stroke rate (0.3% vs 0.8%)
 - Can't use again secondary to antibody formation

Acute Management of MI: Choice of Thrombolytic Agent (continued)

- 90 minute patency better with tPA than SK (70% vs 55% in Euro Coop Study and 70% vs 43% in TIMI-1)
- Patency at 24 hours roughly equal between tPA and SK
- ISIS-3 - mortality identical in head to head comparison of tPA and SK

Thrombolytics: Bottom Line

- Generally choose tPA for large MI's presenting early or in patients who have previously received streptokinase, otherwise choose streptokinase because of cost.

Acute Management of MI: Reperfusion by Primary PTCA

- Theoretic advantages - higher early vessel patency (90% vs 50-75%) and less strokes
- Only 10% US hospitals capable of emergent PTCA
- “Door-to-balloon-inflation” time should be <90 minutes

Reperfusion by Primary PTCA: Comparative Data

- Meta-analysis of 7 trials: 6-week mortality and reinfarction reduced
- PTCA + thrombolytics vs thrombolytics alone much less favorable
- PAMI trial: 395 patients randomized to tPA vs primary angioplasty (12 hours)
 - 97% success rate of PTCA
 - In-hospital mortality PTCA 2.6% and tPA 6.5%
 - Stroke PTCA 0% and tPA 2%
 - Results persisted 6 months

Reperfusion by Primary PTCA: Indications

- Reperfusion candidates (ST-segment elevation <12 hours, etc.) with contraindications to thrombolysis (such as recent CVA)
- Reperfusion candidates as an alternative to thrombolysis in an experienced high volume center
- Suitable candidates in cardiogenic shock

Reperfusion by Primary PTCA


Conclusion

- If quickly available in a good quality center, PTCA is a reasonable alternative to thrombolysis, especially in high-risk patients presenting early, or in patients likely to bleed with thrombolytics


Acute Management of MI: Intra-Arterial Pressure Monitoring

- Indications:
 - Severe hypotension (<90mmHg) or cardiogenic shock
 - Vasopressor agents
 - Potent vasodilators
- Do not leave in for more than 72 hours
 - Thrombosis, infection

IAB Inflation



IAB Deflation



Acute Management of MI: Right Heart Catheter (Swan-Ganz Catheter)

- Indications:
 - Severe or progressive CHF/pulmonary edema
 - Progressive hypotension or cardiogenic shock
 - Suspected mechanical complication of MI (VSD, papillary muscle rupture, pericardial tamponade)
 - Hypotension without pulmonary congestion unresponsive to fluid challenge (uncertain fluid status)

Acute Management of MI: Intra-Aortic Balloon Counterpulsation ("Balloon Pump")

- Improves coronary flow and ↓myocardial O₂ demand
- Indications:
 - Unresponsive cardiogenic shock (as a "bridge" to revascularization)
 - Refractory post-MI angina (as a "bridge" to revascularization)
 - Acute MR or VSD
 - Almost always used to stabilize the patient until more definitive treatment is performed (PCI or CABG)

Long-Term Management After MI

- Aspirin
 - 13% ↓mortality, 31% ↓nonfatal MI
 - Give to nearly everyone lifelong
- Beta-blocker
 - Metoprolol, timolol, propranolol all shown to reduce mortality 1 to 6 years in more than 35,000 patients
 - ↓Mortality 30%
 - Give to nearly everyone indefinitely

Long-Term Management After MI

- Ace Inhibitor
 - Best if started early (25% ↓ mortality)
 - Probably should be stopped in 4-6 weeks for patients with preserved LV function and no CHF symptoms
 - Continue indefinitely if LV dysfunction/CHF is present

Long-Term Management After MI

- Lipid Lowering Agents
 - Prognosis improved even in post-MI with “normal” cholesterol level
 - CARE trial - mean cholesterol 209, LDL 139 at entry showed 24% ↓mortality/nonfatal MI at 5 years with pravastatin
 - Aggressive approach to lipid control (goal LDL<100) mandatory for all patients with CAD

Long-Term Management After MI

- Warfarin (coumadin)
 - Definitely indicated for: post-MI patients with large anterior MI's with/without thrombus or patients with atrial fibrillation (to prevent systemic embolism from LV thrombus)
 - Use for 3 months for LV thrombus or large anterior MI
 - Use indefinitely for atrial fibrillation

Long-Term Management After MI

- Lifestyle modification / Therapeutic Lifestyle Changes (TLC)
 - Diet
 - Exercise
 - Smoking

Long-Term Management After MI


- Exercise testing and stress testing
- Three goals post-MI
 - Assess functional capacity
 - Evaluate efficacy of patient's current medical regimen
 - Risk stratification
- For post-MI patients lacking spontaneous angina who are potential revascularization candidates, an exercise/stress test can be used to select appropriate candidates for coronary angiography

Complication of myocardial infarction

- Arrhythmias
 - Life-threatening:
 - Ventricular tachycardia / ventricular fibrillation – sudden death (I. symptom?)
 - II-III degree AV block – asystolia
- Ventricular failure (LV mass loss >40%)
 - pulmonary congestion
 - cardiogenic shock
 - right ventricular failure – impaired filling pressure (CAVE: NITRO!)
- Mechanical complication
 - mitral papillar rupture – acute mitral regurgitation
 - ventricular septal rupture
 - free wall rupture – pericardial Tamponade

Complication of myocardial infarction

- Arrhythmias
 - Life-threatening:
 - Ventricular tachycardia / ventricular fibrillation – sudden death (I. symptom?)






0%)

ling

regu^A

onad




B

C

Complication of myocardial infarction

- **Arrhythmias**
 - **Life-threatening:**
 - Ventricular tachycardia / ventricular fibrillation – sudden death (I. symptom?)
 - II-III degree AV block – asystolia
- **Ventricular failure (LV mass loss >40%)**
 - pulmonary congestion
 - cardiogenic shock
 - right ventricular failure – impaired filling pressure (CAVE: NITRO!)
- **Mechanical complication**
 - mitral papillar rupture – acute mitral regurgitation
 - ventricular septal rupture
 - free wall rupture – pericardial Tamponade


In the CCU a lot of technical devices (IABP, respirator, dialysator) are necessary



Complication of myocardial infarction

- **Arrhythmias**
 - **Life-threatening:**
 - Ventricular tachycardia / ventricular fibrillation – sudden death (I. symptom?)
 - II-III degree AV block – asystolia
- **Ventricular failure (LV mass loss >40%)**
 - pulmonary congestion
 - cardiogenic shock
 - right ventricular failure – impaired filling pressure (CAVE: NITRO!)
- **Mechanical complication**
 - mitral papillar rupture – acute mitral regurgitation
 - ventricular septal rupture
 - free wall rupture – pericardial Tamponade


Acute mitral flail, chordal rupture



Cardiac rupture syndromes complicating STEMI



Anterior myocardial rupture



Rupture of the ventricular septum



Complete rupture of a necrotic papillary muscle

Pericardial Tamponade



Pericardial Tamponade



Pericardial Tamponade



Conclusion

- The acute coronary syndrome is an acute, life-threatening coronary event
- Need an urgent hospitalisation
- Short anamnesis (mostly the pain!!), physical examination
- rapidly perform an ECG
 - according to the ECG: NSTEMI-ACS or STEMI
- In case of NSTEMI-ACS: risk stratification
- In case of STEMI:
 - If the patient has typical chest pain + typical ECG with acute STEMI – it is enough to diagnose!
 - If the time-window is <12 hours: reperfusion therapy (primary PCI or if pPCI is not feasible thrombolytic therapy)